4,5-Diamino-6-methyl-2-(1-methylpiperidin-4-yl)pyridazin-3-one | 1404065-25-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4,5-Diamino-6-methyl-2-(1-methylpiperidin-4-yl)pyridazin-3-one
• 英文别名: 4,5-diamino-6-methyl-2-(1-methylpiperidin-4-yl)pyridazin-3-one
• CAS: 1404065-25-3
• 化学式: C₁₁H₁₉N₅O
• 分子量: 237.305
• InChiKey: MCEPXRJJGCSPNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  88
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl [1-(4-formyl-3-methoxyphenyl)piperidin-4-yl]carbamate 、 4,5-Diamino-6-methyl-2-(1-methylpiperidin-4-yl)pyridazin-3-one 在 sulfur 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 2.0h， 生成 tert-butyl N-[1-[3-methoxy-4-[7-methyl-5-(1-methylpiperidin-4-yl)-4-oxo-3H-imidazo[4,5-d]pyridazin-2-yl]phenyl]piperidin-4-yl]carbamate
  参考文献：
  名称：

  Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson’s disease model

  摘要：

  The synthesis and structure-activity relationship studies of a series of compounds from imidazopyridazinone scaffold as PDE7 inhibitors are disclosed. Potent analogs such as compounds 7 (31 nM), 8 (27 nM), and 9 (12 nM) were identified. The PDE selectivity and pharmacokinetic profile of compounds 7, 8 and 9 are also disclosed. The adequate CNS penetration of compound 7 in mice allowed it to be tested in the MPTP induced PD model and haloperidol induced catalepsy model to probe the differential pharmacology of PDE7 in the striatal pathway. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.077
• 作为产物：
  描述：

  4,5-二氢-6-甲基哒嗪-3(2H)-酮 在 硫酸 、 溴 、 硝酸 、 铁粉 、 potassium carbonate 、 一水合肼 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 58.0h， 生成 4,5-Diamino-6-methyl-2-(1-methylpiperidin-4-yl)pyridazin-3-one
  参考文献：
  名称：

  Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson’s disease model

  摘要：

  The synthesis and structure-activity relationship studies of a series of compounds from imidazopyridazinone scaffold as PDE7 inhibitors are disclosed. Potent analogs such as compounds 7 (31 nM), 8 (27 nM), and 9 (12 nM) were identified. The PDE selectivity and pharmacokinetic profile of compounds 7, 8 and 9 are also disclosed. The adequate CNS penetration of compound 7 in mice allowed it to be tested in the MPTP induced PD model and haloperidol induced catalepsy model to probe the differential pharmacology of PDE7 in the striatal pathway. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.077

文献信息

• Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson’s disease model
  作者：Abhisek Banerjee、Sandip Patil、Mahesh Y. Pawar、Srinivas Gullapalli、Praveen K. Gupta、Maulik N. Gandhi、Deepak K. Bhateja、Malini Bajpai、Ramachandra Rao Sangana、Girish S. Gudi、Neelima Khairatkar-Joshi、Laxmikant A. Gharat

  DOI：10.1016/j.bmcl.2012.07.077

  日期：2012.10

  The synthesis and structure-activity relationship studies of a series of compounds from imidazopyridazinone scaffold as PDE7 inhibitors are disclosed. Potent analogs such as compounds 7 (31 nM), 8 (27 nM), and 9 (12 nM) were identified. The PDE selectivity and pharmacokinetic profile of compounds 7, 8 and 9 are also disclosed. The adequate CNS penetration of compound 7 in mice allowed it to be tested in the MPTP induced PD model and haloperidol induced catalepsy model to probe the differential pharmacology of PDE7 in the striatal pathway. (C) 2012 Elsevier Ltd. All rights reserved.